What are your thoughts on the medication regimen for a patient with alcohol use disorder in remission and major depressive disorder who is taking vilazodone 40 mg by mouth daily, brexpiprazole (Rexulti) 0.5 mg daily, and bupropion XL (Wellbutrin XL) 300 mg each morning?

Medication Regimen Assessment for Alcohol Use Disorder in Remission and Major Depressive Disorder

This triple-antidepressant regimen (vilazodone + brexpiprazole + bupropion) is reasonable and evidence-supported for treatment-resistant MDD in a patient with alcohol use disorder in remission, though close monitoring for seizure risk and medication interactions is essential.

Rationale for Current Regimen

Vilazodone 40mg Daily (Base Antidepressant)

• Appropriate dosing: The 40mg dose represents the FDA-approved target therapeutic dose for MDD 1
• Efficacy: Demonstrated significant improvement in MADRS scores versus placebo, with onset of action within 1 week and increased remission rates at 6 weeks 2
• Unique mechanism: Combines SSRI activity with 5-HT1A partial agonist properties, potentially offering faster onset and better tolerability than traditional SSRIs 3
• Alcohol use disorder consideration: No specific contraindications in patients with AUD in remission

Brexpiprazole (Rexulti) 0.5mg Daily (Augmentation Agent)

• Evidence-based augmentation: Multiple RCTs demonstrate efficacy of adjunctive brexpiprazole (2-3mg/day is FDA-approved dose) for MDD with inadequate antidepressant response 4, 5, 6
• Current dose concern: The 0.5mg dose is below the therapeutic range—FDA-approved dosing is 2-3mg/day for MDD augmentation
• Efficacy data: At therapeutic doses (2-3mg), brexpiprazole shows:
  • Response rate NNT = 17 4
  • Remission rate NNT = 25 4
  • Improvement across multiple symptom clusters including anhedonia, core depression, and lassitude 7
• Dose recommendation: Consider titrating to 2mg daily (the recommended starting and target dose), as current 0.5mg dose is subtherapeutic

Bupropion XL 300mg Daily (Augmentation/Combination)

• Strong rationale for this patient: Bupropion offers multiple advantages:
  • Lower sexual dysfunction compared to SSRIs 8
  • Alcohol use disorder benefit: Naltrexone-bupropion combinations show efficacy for alcohol abuse disorders 9, and bupropion alone may help maintain sobriety 10
  • No serotonin activity: Unique dopamine/norepinephrine mechanism complements vilazodone's serotonergic effects 3
  • Proven augmentation strategy: Moderate-quality evidence supports augmenting SSRIs with bupropion 11

Critical Safety Considerations

Seizure Risk (Primary Concern)

Bupropion lowers seizure threshold 9, 10:

• Cumulative 2-year seizure risk at ≤450mg/day is 0.48% 9
• Alcohol withdrawal is a contraindication for bupropion 9, 10
• Use with caution in patients with history of alcohol abuse due to increased seizure risk 9
• Since patient is in remission (not actively withdrawing), bupropion is acceptable but requires:
  • Verification of stable remission status
  • Patient education about avoiding alcohol relapse
  • Monitoring for any return to alcohol use

Serotonin Syndrome Risk

• Combining vilazodone (SSRI/5-HT1A agonist) with brexpiprazole (partial dopamine/serotonin agonist) creates theoretical risk
• Monitor closely for agitation, confusion, tremor, hyperthermia, especially during dose adjustments
• Ensure 14-day washout if switching to/from MAOIs 1

Monitoring Requirements

Per ACP guidelines 8:

• Assess within 1-2 weeks of initiation or dose changes
• Monitor for suicidal ideation (especially first 1-2 months)
• Evaluate therapeutic response at 6-8 weeks
• If inadequate response by 6-8 weeks, modify treatment 8

Optimization Recommendations

Immediate Actions:

1. Titrate brexpiprazole from 0.5mg to 2mg daily over 1-2 weeks (current dose is subtherapeutic)
2. Verify alcohol remission stability before continuing bupropion
3. Assess baseline response to current regimen before making changes

If Inadequate Response at 6-8 Weeks:

Per guidelines 8:

• Consider switching strategies rather than adding more medications
• Evaluate whether triple therapy is necessary or if simplification would improve adherence
• Continuation treatment: If response achieved, continue for 4-9 months minimum (first episode) or longer (recurrent episodes) 8

Drug Interactions and Adjustments

Vilazodone-Specific:

• Take with food (required for optimal absorption) 1
• If on strong CYP3A4 inhibitors: reduce vilazodone to 20mg 1
• If on strong CYP3A4 inducers: may increase vilazodone up to 80mg 1

Discontinuation Strategy:

If stopping vilazodone: taper from 40mg→20mg (4 days)→10mg (3 days) 1

Clinical Pearls

Common pitfalls to avoid:

• Using subtherapeutic brexpiprazole doses (current issue)
• Failing to verify alcohol remission stability before continuing bupropion
• Not monitoring closely in first 1-2 weeks for worsening depression or suicidality
• Forgetting that vilazodone must be taken with food
• Inadequate trial duration before declaring treatment failure (need 6-8 weeks minimum)

Advantages of this specific combination:

• Complementary mechanisms (serotonin + dopamine/norepinephrine)
• Bupropion may help prevent alcohol relapse
• Lower sexual dysfunction burden than SSRI monotherapy
• Addresses multiple symptom clusters (anhedonia, core depression, energy)